Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Colorectal cancer (CRC) is the second most common cause of all cancer deaths in Europe and the Western world with a lifetime risk of approximately 5%. Despite several improvements in the treatment of patients with unresectable CRC prognosis is poor and there is the need of developing new treatment strategies for patients with metastatic chemorefractory disease. The S100 calcium binding protein A4 (S100A4) predicts metastasis formation and reduced CRC patient survival. S100A4 was previously identified as transcriptional target of the Wnt/β-catenin signaling pathway. The Food and Drug Administration (FDA)-approved anti-helminthic drug niclosamide is known to intervene in the Wnt/β-catenin pathway signaling, leading to reduced expression of S100A4 linked to restricted in vivo metastasis formation. Thus, we aim at translation of our findings on restricting S100A4-driven metastasis into clinical practice for treating metastasized CRC patients progressing after standard therapy. METHODS/DESIGN: NIKOLO is a phase II, single center, one-arm open-label clinical trial to investigate the safety and efficacy of niclosamide tablets in patients with metastasized CRC progressing under standard therapy. Eligible patients will receive 2 g of orally applied niclosamide once a day and will continue with the treatment once daily till disease progression or toxicity. Toxicities will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03. The primary objective of this trial is to assess the progression free survival after 4 months, secondary objectives are overall survival, time to progression, disease control rate (remission + partial remission + stable disease), and safety. Furthermore, pharmacokinetic analysis will be conducted to evaluate niclosamide plasma concentration. DISCUSSION: This study is expected to provide evidence of the feasibility, toxicity and efficacy of niclosamide in the treatment of patients with metastasized CRC and could help to establish a new treatment option. TRIAL REGISTRATION: The study is registered with ClinicalTrials.gov (NCT02519582) and the European Clinical Trials Database (EudraCT 2014-005151-20).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“niclosamide that decreases Dv1-2 and β-catenin expression [114] and now is in clinical trials for CRC [115]”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 3×
“This design (optimal design after Simon) yields a type I error rate of 0.046 and a power of 0.902.”
InfluentialGrothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“25) estimated according to the recent literature [50, 51].”
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510 · cited 1×
“ses at the time of diagnosis and approximately 25–50% will develop metastases in the course of disease mainly in liver and lung [2, 3].”
Caught up in a Wnt storm: Wnt signaling in cancer
Giles, R. H., van Es, J. H., & Clevers, H. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00005-2 · Cited by 1,482
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402 · cited 1×
“25) estimated according to the recent literature [50, 51].”
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167 · cited 1×
“In recent years prognosis has been improved with median survival rates in clinical trials of up to 30 months [5].”
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992 · cited 1×
“For patients who received an oxaliplatin-based regimen as first-line treatment, the second-line treatment should be irinotecan-based (FOLFIRI or irinotecan alone) [6, 7].”
Factors influencing the natural history of colorectal liver metastases
Stangl, R., Altendorf-Hofmann, A., Charnley, R. M., & Scheele, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92529-1 · Cited by 722
Taylor, A., Primrose, Langeberg, W., Kelsh, Mowat, F., Alexander, D., Choti, M., Poston, G., & Kanas, G. (2012) · Clinical Epidemiology · doi:10.2147/clep.s34285 · Cited by 657 · cited 1×
“ses at the time of diagnosis and approximately 25–50% will develop metastases in the course of disease mainly in liver and lung [2, 3].”
Cited by
Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia
Braga, L., Ali, H., Secco, I., Chiavacci, E., Neves, G., Goldhill, D., Penn, R., Jimenez-Guardeño, J. M., Ortega-Prieto, A. M., Bussani, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03491-6 · Cited by 403
Gajos-Michniewicz, A., & Czyz, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144852 · Cited by 222
Mirabelli, C., Wotring, J. W., Zhang, C. J., McCarty, S. M., Fursmidt, R., Pretto, C. D., Qiao, Y., Zhang, Y., Frum, T., Kadambi, N. S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105815118 · Cited by 223
Emerging agents that target signaling pathways in cancer stem cells
Yang, Y., Li, X., Wang, T., Guo, Q., Xi, T., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00901-6 · Cited by 176
Metadata
- Authors
- Burock, S., Daum, S., Keilholz, U., Neumann, K., Walther, W., & Stein, U.
- Affiliations
- Stiftung Charité (DE)
- Charité – Universitätsmedizin Berlin (DE)
- German Cancer Research Center (DE)
- Max Delbrück Center (DE)
- Corresponding author
- Burock, Susen
- Stein, Ulrike
- Venue
- BMC Cancer
- Published
- 2018-03-15
- Volume
- 18
- Issue
- 1
- Pages
- 297-297
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC5856000
- OpenAlex
- W2800567075
- Cited by
- 117
- References
- 52
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 18 · 2023: 14 · 2022: 18 · 2021: 19 · 2020: 18 · 2019: 11 · 2018: 1
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- PreGoBio program of the Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine
- German Cancer Consortium
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- niclosamide, colorectal cancer, metastatic colorectal cancer, S100A4, Wnt/β-catenin signaling, anti-metastatic therapy, oral anticancer drugs, chemotherapy-refractory disease, progression-free survival, pharmacokinetics, drug safety
- MeSH terms
- S100 Calcium-Binding Protein A4, Administration, Oral, Adult, Aged, Female, Humans, Male, Middle Aged, Neoplasms, Multiple Primary, Niclosamide, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Neoplasms, Second Primary, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial. https://app.cochat.ai/papers/10.1186/s12885-018-4197-9
- The paper
- Burock, S., Daum, S., Keilholz, U., Neumann, K., Walther, W., & Stein, U. (2018). Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial. BMC Cancer. https://doi.org/10.1186/s12885-018-4197-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.